Eventide Asset Management - KALVISTA PHARMACEUTICALS INC ownership

KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 78 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of KALVISTA PHARMACEUTICALS INC
ValueSharesWeighting
Q4 2022$1,867,112
-53.4%
276,2000.0%0.04%
-53.2%
Q3 2022$4,008,000
+118.2%
276,200
+99.0%
0.08%
+243.5%
Q4 2021$1,837,000
-84.2%
138,821
-79.1%
0.02%
-85.0%
Q3 2021$11,616,000
-27.2%
665,6810.0%0.15%
-28.5%
Q2 2021$15,950,000
-54.8%
665,681
-51.5%
0.21%
-59.1%
Q1 2021$35,272,000
+10.6%
1,373,000
-18.3%
0.52%
+7.0%
Q4 2020$31,903,000
+50.8%
1,680,0000.0%0.49%
+18.1%
Q3 2020$21,151,000
+4.0%
1,680,0000.0%0.41%
-6.3%
Q2 2020$20,328,000
+58.2%
1,680,0000.0%0.44%
+6.2%
Q1 2020$12,852,000
-57.0%
1,680,0000.0%0.42%
-50.7%
Q4 2019$29,921,000
+53.5%
1,680,0000.0%0.84%
+30.9%
Q3 2019$19,488,000
-41.3%
1,680,000
+12.0%
0.64%
-36.2%
Q2 2019$33,225,000
+29.0%
1,500,000
+66.7%
1.01%
+14.0%
Q1 2019$25,758,000
+44.9%
900,0000.0%0.89%
+12.6%
Q4 2018$17,775,000
-10.7%
900,0000.0%0.79%
+7.7%
Q3 2018$19,899,000
+172.3%
900,0000.0%0.73%
+141.3%
Q2 2018$7,308,000
-14.3%
900,0000.0%0.30%
-24.1%
Q1 2018$8,532,000
+23.4%
900,000
+26.9%
0.40%
+10.8%
Q4 2017$6,913,000
+162.2%
709,000
+79.0%
0.36%
+141.6%
Q3 2017$2,637,000
+92.9%
396,000
+108.5%
0.15%
+75.3%
Q2 2017$1,367,000
+78.5%
189,900
+93.6%
0.08%
+66.7%
Q1 2017$766,00098,1000.05%
Other shareholders
KALVISTA PHARMACEUTICALS INC shareholders Q3 2019
NameSharesValueWeighting ↓
Saturn V Capital Management LP 1,810,246$17,432,6697.30%
TCG Crossover Management, LLC 3,395,495$32,698,6174.82%
TANG CAPITAL MANAGEMENT LLC 3,440,345$33,130,5224.68%
VR Adviser, LLC 2,916,667$28,087,5032.96%
Frazier Life Sciences Management, L.P. 3,238,859$31,190,2122.07%
Nan Fung Group Holdings Ltd 234,573$2,258,9381.83%
DAFNA Capital Management LLC 605,532$5,831,2731.81%
Opaleye Management Inc. 500,000$4,815,0001.57%
SILVERARC CAPITAL MANAGEMENT, LLC 530,400$5,107,7521.55%
MPM BioImpact LLC 577,958$5,565,7361.49%
View complete list of KALVISTA PHARMACEUTICALS INC shareholders